As of November 7, 2026, 5 holders' latest Schedule 13D or 13G filings report owning 5% or more of Dianthus Therapeutics Inc. The largest reported stake is Fmr LLC's, at 15%. 29 filings are on record since August 14, 2025 (Schedule 13G/A, November 5, 2025).
Sell to companies like Dianthus Therapeutics Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Vanguard Capital Management · Sole voting: 418,713 · Shared voting: 0 · Sole dispositive: 2,846,786 · Shared dispositive: 0 · SCHEDULE 13G, 2026-10-30
- · Reporting person: Sirenia Capital Management LP · Sole voting: 0 · Shared voting: 1,696,751 · Sole dispositive: 0 · Shared dispositive: 1,696,751 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: Wellington Management Group LLP · Sole voting: 0 · Shared voting: 2,795,605 · Sole dispositive: 0 · Shared dispositive: 3,229,882 · SCHEDULE 13G, 2026-08-13
- · Reporting person: T. Rowe Price Investment Management, Inc. · Sole voting: 6,454,315 · Shared voting: 0 · Sole dispositive: 6,632,303 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-08-07
- · Holder: T. Rowe Price Investment Management, Inc. · Percent: 7.1% · SCHEDULE 13G
Dianthus Therapeutics Inc has 29 Schedule 13D or 13G filings on record since 2025-08-14. 5 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Fmr LLC | 15% | 5,970,638 | SCHEDULE 13G/A, 2025-11-05 | 2025-09-30 |
| T. Rowe Price Investment Management, Inc. | 12.1% | 6,632,303 | SCHEDULE 13G/A, 2026-08-07 | 2026-07-31 |
| BlackRock, Inc. | 6.4% | 3,504,166 | SCHEDULE 13G/A, 2026-07-28 | 2026-06-30 |
| Wellington Management Group LLP | 5.9% | 3,229,882 | SCHEDULE 13G, 2026-08-13 | 2026-06-30 |
| Vanguard Capital Management | 5.08% | 2,846,786 | SCHEDULE 13G, 2026-10-30 | 2026-09-30 |
| Fairmount Funds Management LLC | 4.9% | 2,139,635 | SCHEDULE 13D/A, 2025-11-25 | 2025-11-21 |
| Avidity Partners Management LP | 4.9% | 2,104,184 | SCHEDULE 13D/A, 2025-11-19 | 2025-11-17 |
| RA Capital Management, L.P. | 4.8% | 2,611,733 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| Octagon Capital Advisors LP | 3.6% | 1,946,667 | SCHEDULE 13G/A, 2026-05-14 | 2026-03-31 |
| BCLS Fund III Investments, LP | 3.1% | 1,315,892 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
| Venrock Healthcare Capital Partners III, L.P. | 3.1% | 1,000,000 | SCHEDULE 13G/A, 2025-08-14 | 2025-06-30 |
| Sirenia Capital Management LP | 3.1% | 1,696,751 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| Vestal Point Capital, LP | 3% | 1,180,000 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
| Point72 Asset Management, L.P. | 1.2% | 643,599 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| Deep Track Capital, LP | 0% | 0 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
Holding shares or following this stake? See who's behind Dianthus Therapeutics Inc and the warning signs.
Free to see. No signup.
Keep reading
More on Dianthus Therapeutics Inc and the records around it.
Dianthus Therapeutics Inc elsewhere on the record
Companies that share a holder
- BCLS Fund III Investments, LP also filed stake reports on 3 other companies: ADARx Pharmaceuticals, Inc. (Oct 2026), Heartflow, Inc. (Aug 2026), CIDARA THERAPEUTICS, INC. (Feb 2026)
- Avidity Partners Management LP also filed stake reports on 5 other companies: Context Therapeutics Inc. (May 2026), Immunic, Inc. (Apr 2026), Perspective Therapeutics, Inc. (Mar 2026)
- Octagon Capital Advisors LP also filed stake reports on 8 other companies: Precision BioSciences, Inc. (Nov 2026), Context Therapeutics Inc. (Jul 2026), Corbus Pharmaceuticals Holdings, Inc. (May 2026)
Watch Dianthus Therapeutics Inc
Get an email when Dianthus Therapeutics Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Dianthus Therapeutics Inc?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Dianthus Therapeutics Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Dianthus Therapeutics Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
29 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 6,454,315 | 0 | 6,632,303 | 0 | SCHEDULE 13G/A, 2026-08-07 |
| BlackRock, Inc. | 3,433,718 | 0 | 3,504,166 | 0 | SCHEDULE 13G/A, 2026-07-28 |
| Wellington Management Group LLP | 0 | 2,795,605 | 0 | 3,229,882 | SCHEDULE 13G, 2026-08-13 |
| Wellington Group Holdings LLP | 0 | 2,795,605 | 0 | 3,229,882 | SCHEDULE 13G, 2026-08-13 |
| Wellington Investment Advisors Holdings LLP | 0 | 2,795,605 | 0 | 3,229,882 | SCHEDULE 13G, 2026-08-13 |
| Wellington Management Company LLP | 0 | 2,774,221 | 0 | 3,033,523 | SCHEDULE 13G, 2026-08-13 |
| Vanguard Capital Management | 418,713 | 0 | 2,846,786 | 0 | SCHEDULE 13G, 2026-10-30 |
| Sirenia Capital Management LP | 0 | 1,696,751 | 0 | 1,696,751 | SCHEDULE 13G/A, 2026-08-14 |
| Alex Silverstein | 0 | 1,696,751 | 0 | 1,696,751 | SCHEDULE 13G/A, 2026-08-14 |
The latest filing identifies Dianthus Therapeutics Inc by CUSIP 252828108 and gives its principal executive office as 7 Times Square, 43rd Floor, New York, NY 10036 (SCHEDULE 13G, 2026-10-30).
Purpose of Transaction (Item 4)
Fairmount Funds Management LLC
Item 4 of the Statement is hereby amended and supplemented as follows: On November 24, 2025, Fund II provided notice to the Company to decrease the Maximum Percentage of the Pre-Funded Warrants from 9.99% to 4.99%, such that the Reporting Persons may only exercise the Pre-Funded Warrants to the extent that after giving effect to such exercise the holders thereof and their affiliates and any persons who are members of a Section 13(d) group with the holders would beneficially own in the aggregate no more than 4.99% of the outstanding Common Stock of the Company. By notice to the Company, the Reporting Persons may increase or decrease the Maximum Percentage to any other percentage not in excess of 19.99%; provided that any such increase will not be effective until the 61st day after such notice is delivered to the Company. The decrease of the Maximum Percentage became effective immediately. The Reporting Persons do not have any present plans or proposals that relate to or would result in any of the actions described in subparagraphs (a) through (j) of Item 4 of Schedule 13D, although, the Reporting Persons, at any time and from time to time, may review, reconsider and change their position and/or change their purpose and/or develop such plans and may seek to influence management or the board of directors of the Company with respect to the business and affairs of the Company and may from time to time consider pursuing or proposing such matters with advisors, the Company or …The first part of Item 4 of the SCHEDULE 13D/A filed 2025-11-25; the filing has the rest
Avidity Partners Management LP
The Reporting Persons are filing this Amendment No. 3 to report a greater than 1.00% decrease in the percentage of shares of Common Stock beneficially owned by the Reporting Persons due to the sale of shares of Common Stock by private investment funds managed by Avidity Partners Management LP, including Avidity Private Master Fund I LP. Although the Reporting Persons do not have any specific plan or proposal to acquire, transfer or dispose of Common Stock at the time of this filing, consistent with their investment purpose, the Reporting Persons may, either directly or through one or more affiliates, from time to time or at any time and subject to price, market and general economic and fiscal conditions and other factors, acquire or seek to acquire additional shares of Common Stock in the open market, in privately negotiated transactions or otherwise, or dispose of or seek to dispose of all or a portion of such shares of Common Stock now owned or hereafter acquired. The Reporting Persons reserve the right to change their intention with respect to any or all of the matters required to be disclosed in this Item 4. The Reporting Persons have not made a determination regarding a maximum or minimum number of shares of Common Stock or other securities of the Issuer that it may hold at any point in time. Except as set forth herein and below, or as would occur upon completion of any of the matters discussed herein, the Reporting Persons have no present plans or proposals that …The first part of Item 4 of the SCHEDULE 13D/A filed 2025-11-19; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-14 | Vestal Point Capital, LP | 9.95% | SCHEDULE 13G/A |
| 2025-08-14 | Point72 Asset Management, L.P. | 4.5% | SCHEDULE 13G/A |
| 2025-08-14 | BCLS Fund III Investments, LP | 7.5% | SCHEDULE 13G/A |
| 2025-08-14 | Venrock Healthcare Capital Partners III, L.P. | 3.1% | SCHEDULE 13G/A |
| 2025-09-12 | Point72 Asset Management, L.P. | 5.3% | SCHEDULE 13G |
| 2025-09-15 | Fairmount Funds Management LLC | 9.9% | SCHEDULE 13D/A |
| 2025-11-05 | Fmr LLC | 15% | SCHEDULE 13G/A |
| 2025-11-12 | Wellington Management Group LLP | 6.5% | SCHEDULE 13G |
| 2025-11-14 | Vestal Point Capital, LP | 3% | SCHEDULE 13G/A |
| 2025-11-14 | Deep Track Capital, LP | 0% | SCHEDULE 13G/A |
| 2025-11-14 | BCLS Fund III Investments, LP | 3.1% | SCHEDULE 13G/A |
| 2025-11-14 | Octagon Capital Advisors LP | 6.1% | SCHEDULE 13G/A |
| 2025-11-14 | RA Capital Management, L.P. | 9.5% | SCHEDULE 13G/A |
| 2025-11-19 | Avidity Partners Management LP | 4.9% | SCHEDULE 13D/A |
| 2025-11-25 | Fairmount Funds Management LLC | 4.9% | SCHEDULE 13D/A |
| 2026-02-17 | Point72 Asset Management, L.P. | 6.9% | SCHEDULE 13G/A |
| 2026-02-17 | RA Capital Management, L.P. | 6% | SCHEDULE 13G/A |
| 2026-04-27 | BlackRock, Inc. | 5.1% | SCHEDULE 13G |
| 2026-05-14 | Octagon Capital Advisors LP | 3.6% | SCHEDULE 13G/A |
| 2026-05-15 | Wellington Management Group LLP | 4.8% | SCHEDULE 13G/A |
| 2026-05-15 | Sirenia Capital Management LP | 5.3% | SCHEDULE 13G |
| 2026-05-15 | Point72 Asset Management, L.P. | 1.2% | SCHEDULE 13G/A |
| 2026-05-15 | RA Capital Management, L.P. | 4.8% | SCHEDULE 13G/A |
| 2026-07-28 | BlackRock, Inc. | 6.4% | SCHEDULE 13G/A |
| 2026-08-07 | T. Rowe Price Investment Management, Inc. | 7.1% | SCHEDULE 13G |
| 2026-08-07 | T. Rowe Price Investment Management, Inc. | 12.1% | SCHEDULE 13G/A |
| 2026-08-13 | Wellington Management Group LLP | 5.9% | SCHEDULE 13G |
| 2026-08-14 | Sirenia Capital Management LP | 3.1% | SCHEDULE 13G/A |
| 2026-10-30 | Vanguard Capital Management | 5.08% | SCHEDULE 13G |
Questions about who owns Dianthus Therapeutics Inc
Who owns Dianthus Therapeutics Inc?
On this page, 5 holders' latest ownership filings report 5% or more of Dianthus Therapeutics Inc: Fmr LLC (15%, Schedule 13G/A, filed 2025-11-05), T. Rowe Price Investment Management, Inc. (12.1%, Schedule 13G/A, filed 2026-08-07), BlackRock, Inc. (6.4%, Schedule 13G/A, filed 2026-07-28), Wellington Management Group LLP (5.9%, Schedule 13G, filed 2026-08-13) and Vanguard Capital Management (5.08%, Schedule 13G, filed 2026-10-30).
Who are the largest shareholders of Dianthus Therapeutics Inc?
By the share each holder's latest filing reports, the largest holders of Dianthus Therapeutics Inc on this page are Fmr LLC (15%), T. Rowe Price Investment Management, Inc. (12.1%) and BlackRock, Inc. (6.4%).
When did Fmr LLC buy into Dianthus Therapeutics Inc?
The filings give report dates, not purchase dates. The earliest filing from Fmr LLC on this page is the Schedule 13G/A, filed 2025-11-05, reporting 15%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 29 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Dianthus Therapeutics Inc. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.